Honasa Consumer calls off Fluence Pharma deal over unmet conditions
- Honasa Consumer terminated its proposed acquisition of a 58% stake in Fluence Pharma
- The deal was called off due to non-fulfilment of closing conditions in the Share Purchase Agreement
- The announcement was made on August 25, 2026, following an initial proposal in June 2026
- Honasa remains committed to its nutraceutical strategy and will evaluate further opportunities

*this image is generated using AI for illustrative purposes only.
Honasa Consumer Limited terminated its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited. The cancellation was announced on August 25, 2026, citing the non-fulfilment of closing conditions specified in the Share Purchase Agreement.
The disclosure follows an earlier notification dated June 23, 2026, which had outlined the proposed acquisition subject to the completion of specific conditions precedent.
Regulatory Disclosure
The update was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited regarding the termination of the transaction.
Strategic Outlook
Honasa stated it remains committed to its nutraceutical strategy. The company indicated it will continue to evaluate organic and inorganic opportunities to build a consumer-focused business in this category.
Transaction Details
| Parameter | Details |
|---|---|
| Target Company | Fluence Pharma Private Limited |
| Proposed Stake | 58% equity |
| Status | Called off |
| Reason | Non-fulfilment of closing conditions |
| Announcement Date | August 25, 2026 |
The disclosure was signed by Gaurav Pandit, Company Secretary and Compliance Officer, on behalf of Honasa Consumer Limited.
Historical Stock Returns for Mamaearth
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.08% | +0.80% | +8.23% | +58.84% | +62.21% | +44.02% |
How might the termination of the Fluence Pharma acquisition impact Honasa Consumer's near-term revenue growth projections and market valuation?
Will Honasa Consumer prioritize organic R&D expansion or seek alternative inorganic targets to accelerate its nutraceutical portfolio?
What specific closing conditions were not met, and does this indicate broader regulatory or operational hurdles in the Indian nutraceutical M&A landscape?


































